BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:4-13. [PMID: 32319693 DOI: 10.1002/hep.31288] [Cited by in Crossref: 254] [Cited by in F6Publishing: 301] [Article Influence: 254.0] [Reference Citation Analysis]
Number Citing Articles
1 Yao M, Cai Y, Wu ZJ, Zhou P, Sai WL, Wang DF, Wang L, Yao DF. Effects of targeted-edited oncogenic insulin-like growth factor-1 receptor with specific-sgRNA on biological behaviors of HepG2 cells. World J Clin Cases 2022; 10(28): 10017-10030 [DOI: 10.12998/wjcc.v10.i28.10017] [Reference Citation Analysis]
2 Devan AR, Pavithran K, Nair B, Murali M, Nath LR. Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma. World J Gastroenterol 2022; 28(36): 5250-5264 [DOI: 10.3748/wjg.v28.i36.5250] [Reference Citation Analysis]
3 Amadou A, Sighoko D, Coulibaly B, Traoré C, Kamaté B, Mallé BS, de Seze M, Kemayou Yoghoum FN, Biyogo Bi Eyang S, Bourgeois D, Curado MP, Bayo S, Gormally E, Hainaut P. Decrease in liver cancer incidence rates in Bamako, Mali over 28 years of population-based cancer registration (1987-2015). World J Hepatol 2022; 14(9): 1767-1777 [DOI: 10.4254/wjh.v14.i9.1767] [Reference Citation Analysis]
4 Verma M, Kalman R, Horrow J, Gallagher M, Woodrell C, Navarro V. Feasibility of a Palliative Care Intervention within Routine Care of Hepatocellular Carcinoma: A Pilot Randomized Controlled Trial. J Palliat Med 2022. [PMID: 36149682 DOI: 10.1089/jpm.2022.0338] [Reference Citation Analysis]
5 He X, Li Y, Ma Y, Fu Y, Xun X, Cui Y, Dong Z. Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats. Molecules 2022;27:6190. [DOI: 10.3390/molecules27196190] [Reference Citation Analysis]
6 Mohamed EA, Giama NH, Abdalla AO, Shaleh HM, Oseini AM, Ali HA, Ahmed F, Taha W, Ahmed Mohammed H, Cvinar J, Waaeys IA, Ali H, Allotey LK, Ali AO, Mohamed SA, Harmsen WS, Ahmmad EM, Bajwa NA, Afgarshe MD, Shire AM, Balls-Berry JE, Roberts LR. High prevalence of chronic viral hepatitis B and C in Minnesota Somalis contributes to rising hepatocellular carcinoma incidence. World J Gastroenterol 2022; 28(35): 5217-5229 [DOI: 10.3748/wjg.v28.i35.5217] [Reference Citation Analysis]
7 Leyh C, Heucke N, Schotten C, Büchter M, Bechmann LP, Wichert M, Dechêne A, Herrmann K, Heider D, Sydor S, Lemmer P, Ludwig JM, Pospiech J, Theysohn J, Damm R, March C, Powerski M, Pech M, Özcürümez M, Weigt J, Keitel V, Lange CM, Schmidt H, Canbay A, Best J, Gerken G, Manka PP. LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis. Cancers 2022;14:4584. [DOI: 10.3390/cancers14194584] [Reference Citation Analysis]
8 Hirsova P, Revelo XS. Editorial: Immune mechanisms of inflammation in NASH. Front Endocrinol 2022;13:1039238. [DOI: 10.3389/fendo.2022.1039238] [Reference Citation Analysis]
9 Delangre E, Oppliger E, Berkcan S, Gjorgjieva M, Correia de Sousa M, Foti M. S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma. IJMS 2022;23:11030. [DOI: 10.3390/ijms231911030] [Reference Citation Analysis]
10 Costante F, Airola C, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. World J Gastrointest Oncol 2022; 14(9): 1622-1636 [DOI: 10.4251/wjgo.v14.i9.1622] [Reference Citation Analysis]
11 Fu X, Zhang W, Li S, Ling N, Yang Y, Dazhi Z. Identification of alanine aminotransferase 1 interaction network via iTRAQ-based proteomics in alternating migration, invasion, proliferation and apoptosis of HepG2 cells. Aging. [DOI: 10.18632/aging.204286] [Reference Citation Analysis]
12 Suo H, Hochnadel I, Petriv N, Franke R, Schmidt J, Limanska N, Tugai A, Jedicke N, Broenstrup M, Manns MP, Yevsa T. Elucidating the mechanism behind and investigating the efficacy of Traditional Chinese Medicine and Traditional Tibetan Medicine in combination with standard therapeutics in hepatocellular carcinoma and cholangiocarcinoma in vitro. Front Pharmacol 2022;13:906468. [DOI: 10.3389/fphar.2022.906468] [Reference Citation Analysis]
13 Sucularli C. Identification of BRIP1, NSMCE2, ANAPC7, RAD18 and TTL from chromosome segregation gene set associated with hepatocellular carcinoma. Cancer Genet 2022;268-269:28-36. [PMID: 36126360 DOI: 10.1016/j.cancergen.2022.09.003] [Reference Citation Analysis]
14 Ugai T, Sasamoto N, Lee HY, Ando M, Song M, Tamimi RM, Kawachi I, Campbell PT, Giovannucci EL, Weiderpass E, Rebbeck TR, Ogino S. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol 2022. [PMID: 36068272 DOI: 10.1038/s41571-022-00672-8] [Reference Citation Analysis]
15 Chen W, Yang Z, Chen Y, Trivanovic D. A Novel Oxidative Phosphorylation-Associated Gene Signature for Prognosis Prediction in Patients with Hepatocellular Carcinoma. Disease Markers 2022;2022:1-20. [DOI: 10.1155/2022/3594901] [Reference Citation Analysis]
16 Zhang B, Wang Z. A novel pyroptosis-regulated gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma. Front Mol Biosci 2022;9:890215. [DOI: 10.3389/fmolb.2022.890215] [Reference Citation Analysis]
17 Yao M, Cheng S, Zhai X, Zhao H, Hong J, Li X, Meng Y, Chen W, Liu Y. Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis. Applied Bionics and Biomechanics 2022;2022:1-9. [DOI: 10.1155/2022/9084852] [Reference Citation Analysis]
18 Bang S, Jee S, Son H, Cha H, Sim J, Kim Y, Park H, Myung J, Kim H, Paik S. Clinicopathological Implications of ASAP1 Expression in Hepatocellular Carcinoma. Pathol Oncol Res 2022;28:1610635. [DOI: 10.3389/pore.2022.1610635] [Reference Citation Analysis]
19 Decarli K, Strosberg J, Almhanna K. Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update. Cancers 2022;14:4201. [DOI: 10.3390/cancers14174201] [Reference Citation Analysis]
20 Luo X, Wang Y, Zhang X, Liu W, Shi Z. The Clinical Value of Long Noncoding RNA DDX11-AS1 as a Biomarker for the Diagnosis and Prognosis of Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-8. [DOI: 10.1155/2022/5735462] [Reference Citation Analysis]
21 Alafnan A, Alamri A, Alanazi J, Hussain T. Farnesiferol C Exerts Antiproliferative Effects on Hepatocellular Carcinoma HepG2 Cells by Instigating ROS-Dependent Apoptotic Pathway. Pharmaceuticals 2022;15:1070. [DOI: 10.3390/ph15091070] [Reference Citation Analysis]
22 Cheng CC, Ho AS, Peng CL, Chang J, Sie ZL, Wang CL, Chen YL, Chen CY. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8+ T cell activation to eradicate hepatocellular carcinoma. Int Immunopharmacol 2022;112:109110. [PMID: 36037651 DOI: 10.1016/j.intimp.2022.109110] [Reference Citation Analysis]
23 Sasaki-tanaka R, Ray R, Moriyama M, Ray RB, Kanda T. Molecular Changes in Relation to Alcohol Consumption and Hepatocellular Carcinoma. IJMS 2022;23:9679. [DOI: 10.3390/ijms23179679] [Reference Citation Analysis]
24 Liu X, Xie W, Meng S, Kang X, Liu Y, Guo L, Wang C. Small Nucleolar RNAs and Their Comprehensive Biological Functions in Hepatocellular Carcinoma. Cells 2022;11:2654. [DOI: 10.3390/cells11172654] [Reference Citation Analysis]
25 Duberg AS, Lybeck C, Fält A, Montgomery S, Aleman S. Reply Comment on risk of HCC with chronic hepatitis B infection in Sweden. Hepatol Commun 2022. [PMID: 36017781 DOI: 10.1002/hep4.2083] [Reference Citation Analysis]
26 Xia J, Qin X, Zhang L, Liu S, Shi X, Ren H. Roles and regulation of histone acetylation in hepatocellular carcinoma. Front Genet 2022;13:982222. [DOI: 10.3389/fgene.2022.982222] [Reference Citation Analysis]
27 Guerrero L, Paradela A, Corrales FJ. Targeted Proteomics for Monitoring One-Carbon Metabolism in Liver Diseases. Metabolites 2022;12:779. [DOI: 10.3390/metabo12090779] [Reference Citation Analysis]
28 Haque A, Sahu V, Lombardo JL, Xiao L, George B, Wolff RA, Morris JS, Rashid A, Kopchick JJ, Kaseb AO, Amin HM. Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. J Hepatocell Carcinoma 2022;9:823-37. [PMID: 35996397 DOI: 10.2147/JHC.S368208] [Reference Citation Analysis]
29 Cui Y, Li Y, Guo C, Li Y, Ma Y, Dong Z. Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats. Molecules 2022;27:5419. [DOI: 10.3390/molecules27175419] [Reference Citation Analysis]
30 Wang T, Zhou Z, Wang X, You L, Li W, Zheng C, Zhang J, Wang L, Kong X, Gao Y, Sun X. Comprehensive analysis of nine m7G-related lncRNAs as prognosis factors in tumor immune microenvironment of hepatocellular carcinoma and experimental validation. Front Genet 2022;13:929035. [DOI: 10.3389/fgene.2022.929035] [Reference Citation Analysis]
31 Nishio T, Ito T, Hata K, Taura K, Hatano E. Current status of liver transplantation for non‐B non‐C liver cirrhosis and hepatocellular carcinoma. Annals of Gastroent Surgery. [DOI: 10.1002/ags3.12612] [Reference Citation Analysis]
32 Vidal AC, Moylan CA, Wilder J, Grant DJ, Murphy SK, Hoyo C. Racial disparities in liver cancer: Evidence for a role of environmental contaminants and the epigenome. Front Oncol 2022;12:959852. [DOI: 10.3389/fonc.2022.959852] [Reference Citation Analysis]
33 Zunica ERM, Heintz EC, Axelrod CL, Kirwan JP. Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:4051. [PMID: 36011044 DOI: 10.3390/cancers14164051] [Reference Citation Analysis]
34 Ahluwalia S, Ahmad B, Salim U, Ghosh D, Kamuju V, Ghosh A, Dabeer K, Menon MB, Vivekanandan P. Hepatitis B Virus-Encoded HBsAg Contributes to Hepatocarcinogenesis by Inducing the Oncogenic Long Noncoding RNA LINC00665 through the NF-κB Pathway. Microbiol Spectr 2022;:e0273121. [PMID: 35993712 DOI: 10.1128/spectrum.02731-21] [Reference Citation Analysis]
35 Kim JY, Kim J, Lim Y, Gwak G, Yeo I, Kim Y, Lee J, Shin D, Lee J, Kim Y. Proteome Multimarker Panel for the Early Detection of Hepatocellular Carcinoma: Multicenter Derivation, Validation, and Comparison. ACS Omega. [DOI: 10.1021/acsomega.2c02926] [Reference Citation Analysis]
36 Harrison AC, Kanwal F, Asrani SK, Thrift AP, Amos CI, Jibaja-weiss ML, Montealegre JR, Hwang JP, Singal AG, El-serag HB. The Texas collaborative center for hepatocellular cancer: Reducing liver cancer mortality in Texas through coordination, collaboration and advocacy. Front Oncol 2022;12:953933. [DOI: 10.3389/fonc.2022.953933] [Reference Citation Analysis]
37 Li B, Fu Y, Xie M, Feng L, Niu X, Que L, You Z. Gold-based nanoparticles realize photothermal and photodynamic synergistic treatment of liver cancer and improve the anaerobic tumor microenvironment under near-infrared light. Front Bioeng Biotechnol 2022;10:957349. [DOI: 10.3389/fbioe.2022.957349] [Reference Citation Analysis]
38 Yao L, Wen X, Guo W, Fang J, Zhang X, Guo Z, Huang J, Li Y. Novel Radiolabeled TMTP1 for Long-Acting Hepatocellular Carcinoma Therapeutics. Mol Pharm 2022. [PMID: 35972772 DOI: 10.1021/acs.molpharmaceut.2c00270] [Reference Citation Analysis]
39 Norman EML, Weil J, Philip J. Hepatocellular carcinoma and its impact on quality of life: A review of the qualitative literature. Eur J Cancer Care (Engl) 2022;:e13672. [PMID: 35974658 DOI: 10.1111/ecc.13672] [Reference Citation Analysis]
40 Zhao R, Li H, Ge W, Zhu X, Zhu L, Wan X, Wang G, Pan H, Lu J, Han W. Comprehensive Analysis of Genomic Alterations in Hepatoid Adenocarcinoma of the Stomach and Identification of Clinically Actionable Alterations. Cancers 2022;14:3849. [DOI: 10.3390/cancers14163849] [Reference Citation Analysis]
41 Shekh R, Tiwari RK, Ahmad A, Ahmad I, Alabdallah NM, Saeed M, Ansari IA, Mishra A, Ashfaque M, Bajpai P. Ethanolic extract of Coleus aromaticus leaves impedes the proliferation and instigates apoptotic cell death in liver cancer HepG2 cells through repressing JAK/STAT cascade. J Food Biochem 2022;:e14368. [PMID: 35945689 DOI: 10.1111/jfbc.14368] [Reference Citation Analysis]
42 Hernandez BY, Biggs J, Zhu X, Sotto P, Nagata M, Mendez AJP, Paulino Y. Environmental Exposure to Cyanobacteria Hepatotoxins in a Pacific Island Community: A Cross-Sectional Assessment. Microorganisms 2022;10:1607. [DOI: 10.3390/microorganisms10081607] [Reference Citation Analysis]
43 Li X, Ito M, Aoyagi H, Murayama A, Aizaki H, Fukasawa M, Kato T, Wakita T, Suzuki T. Development and Use of a Kinetical and Real-Time Monitoring System to Analyze the Replication of Hepatitis C Virus. Int J Mol Sci 2022;23:8711. [PMID: 35955844 DOI: 10.3390/ijms23158711] [Reference Citation Analysis]
44 Yuan J, Wang Y, Wang X, Zhang W, Ding R, Yue S, Li X. Construction and experimental verification of user-friendly molecular subtypes mediated by immune-associated genes in hepatocellular carcinoma. Front Oncol 2022;12:924059. [DOI: 10.3389/fonc.2022.924059] [Reference Citation Analysis]
45 Zhu X, Zhu J, Chen Y, Liu Y, Lu J, Sun J, Peng S, Chen M, Du Y. Bioinformatics analysis and experimental verification of the prognostic and biological significance mediated by fatty acid metabolism related genes for hepatocellular carcinoma. Front Oncol 2022;12:972744. [DOI: 10.3389/fonc.2022.972744] [Reference Citation Analysis]
46 Sun LY, Li ZL, Yang T. Editorial: non-viral hepatocellular carcinoma surveillance-an increasingly severe public health issue. Aliment Pharmacol Ther 2022;56:748-9. [PMID: 35879900 DOI: 10.1111/apt.17116] [Reference Citation Analysis]
47 Li X, Xie S, Shen J, Chen S, Yan J. Construction of functionalized ruthenium-modified selenium coated with pH-responsive silk fibroin nanomaterials enhanced anticancer efficacy in hepatocellular cancer. Process Biochemistry 2022. [DOI: 10.1016/j.procbio.2022.08.029] [Reference Citation Analysis]
48 Cao J, Xu Y, Liu X, Cai Y, Luo B. Innovative signature establishment using lymphangiogenesis-related lncRNA pairs to predict prognosis of hepatocellular carcinoma. Heliyon 2022;8:e10215. [PMID: 36033263 DOI: 10.1016/j.heliyon.2022.e10215] [Reference Citation Analysis]
49 Atif J, Thoeni C, Bader GD, McGilvray ID, MacParland SA. Unraveling the Complexity of Liver Disease One Cell at a Time. Semin Liver Dis 2022;42:250-70. [PMID: 36008091 DOI: 10.1055/s-0042-1755272] [Reference Citation Analysis]
50 Scherübl H. [Metabolic syndrome and cancer risk]. Dtsch Med Wochenschr 2022;147:1068-77. [PMID: 35970189 DOI: 10.1055/a-1868-9164] [Reference Citation Analysis]
51 Parola M. Follistatin-like protein 1 and chronic liver disease progression: a novel pro-inflammatory and pro-fibrogenic mediator? Ann Transl Med 2022;10:841. [PMID: 36035001 DOI: 10.21037/atm-22-3561] [Reference Citation Analysis]
52 Marsh-Wakefield F, Ferguson AL, Liu K, Santhakumar C, McCaughan G, Palendira U. Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:17588359221113270. [PMID: 35898965 DOI: 10.1177/17588359221113270] [Reference Citation Analysis]
53 Renzulli M, Pecorelli A, Brandi N, Brocchi S, Tovoli F, Granito A, Carrafiello G, Ierardi AM, Golfieri R. The Feasibility of Liver Biopsy for Undefined Nodules in Patients under Surveillance for Hepatocellular Carcinoma: Is Biopsy Really a Useful Tool? JCM 2022;11:4399. [DOI: 10.3390/jcm11154399] [Reference Citation Analysis]
54 Mattos ÂZ, Debes JD, Vogel A, Arrese M, Revelo X, Pase THS, Manica M, Mattos AA. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy? . World J Gastroenterol 2022; 28(28): 3595-3607 [DOI: 10.3748/wjg.v28.i28.3595] [Reference Citation Analysis]
55 El Halabi J, LaGuardia L, Walsh RM, Kwon CHD, Menon KVN, Liska D, Burke CA. Hepatocellular carcinoma and solid pseudopapillary neoplasm of the pancreas complicating familial adenomatous polyposis: two cases and review of the literature. Fam Cancer 2022. [PMID: 35896845 DOI: 10.1007/s10689-022-00305-0] [Reference Citation Analysis]
56 Zhu L, Li H, Xu J, Li J, Cheng M, Meng X, Huang C, Li J. Advancements in the Alcohol-Associated Liver Disease Model. Biomolecules 2022;12:1035. [DOI: 10.3390/biom12081035] [Reference Citation Analysis]
57 Talib WH, Daoud S, Mahmod AI, Hamed RA, Awajan D, Abuarab SF, Odeh LH, Khater S, Al Kury LT. Plants as a Source of Anticancer Agents: From Bench to Bedside. Molecules 2022;27:4818. [DOI: 10.3390/molecules27154818] [Reference Citation Analysis]
58 Fu Y, Liu S, Rodrigues RM, Han Y, Guo C, Zhu Z, He Y, Mackowiak B, Feng D, Gao B, Zeng S, Shen H. Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism. Int J Biol Sci 2022;18:4341-56. [PMID: 35864952 DOI: 10.7150/ijbs.71134] [Reference Citation Analysis]
59 Wei C, Deng X, Gao S, Wan X, Chen J. Cantharidin Inhibits Proliferation of Liver Cancer by Inducing DNA Damage via KDM4A-Dependent Histone H3K36 Demethylation. Evid Based Complement Alternat Med 2022;2022:2197071. [PMID: 35860003 DOI: 10.1155/2022/2197071] [Reference Citation Analysis]
60 Dong S, Li Z, Kong J, Wu S, Gao J, Sun W. Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2. Int J Hyperthermia 2022;39:888-96. [PMID: 35848416 DOI: 10.1080/02656736.2022.2093995] [Reference Citation Analysis]
61 Park HM, Won YJ, Kang MJ, Park SJ, Kim SW, Jung KW, Han SS. Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea. J Korean Med Sci 2022;37:e216. [PMID: 35851861 DOI: 10.3346/jkms.2022.37.e216] [Reference Citation Analysis]
62 Jing W, Peng R, Li X, Lv S, Duan Y, Jiang S, Wang F. Study on the Prognostic Values of TTC36 Correlated with Immune Infiltrates and Its Methylation in Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-15. [DOI: 10.1155/2022/7267131] [Reference Citation Analysis]
63 Zhu J, Han T, Zhao S, Zhu Y, Ma S, Xu F, Bai T, Tang Y, Xu Y, Liu L. Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma. Front Oncol 2022;12:933210. [DOI: 10.3389/fonc.2022.933210] [Reference Citation Analysis]
64 Feng X, Guo Y, Tu H, Li S, Chen C, Sun M, Wang S, Li B, Wu X, Song Z. Temporal changes in serum uric acid and risk for metabolic syndrome: a longitudinal cohort study. Diabetol Metab Syndr 2022;14. [DOI: 10.1186/s13098-022-00861-6] [Reference Citation Analysis]
65 Sukowati C, Cabral LKD, Tiribelli C. Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle. Ann Hepatol 2022;27:100740. [PMID: 35809835 DOI: 10.1016/j.aohep.2022.100740] [Reference Citation Analysis]
66 Chang JI, Sinn DH, Jeong WK, Hwang JA, Won HY, Kim K, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development. Scand J Gastroenterol 2022;:1-8. [PMID: 35786290 DOI: 10.1080/00365521.2022.2093124] [Reference Citation Analysis]
67 Cao L, Han Y, Pei L, Yue Z, Liu B, Cui J, Jia M, Wang H. A Serum Metabolite Classifier for the Early Detection of Type 2 Diabetes Mellitus-Positive Hepatocellular Cancer. Metabolites 2022;12:610. [DOI: 10.3390/metabo12070610] [Reference Citation Analysis]
68 Feng S, Ni P, Gong Y, Geng B, Li H, Miao C, Fan R, Galstyan L, Pan D, Chen F, Li H. Synergistic anti-tumor therapy by a homotypic cell membrane-cloaked biomimetic nanocarrier with exceptionally potent activity against hepatic carcinoma. Nano Res . [DOI: 10.1007/s12274-022-4462-8] [Reference Citation Analysis]
69 Gilles H, Garbutt T, Landrum J. Hepatocellular Carcinoma. Critical Care Nursing Clinics of North America 2022. [DOI: 10.1016/j.cnc.2022.04.004] [Reference Citation Analysis]
70 D'Alessandro LA, Klingmüller U, Schilling M. Deciphering signal transduction networks in the liver by mechanistic mathematical modelling. Biochem J 2022;479:1361-74. [PMID: 35748700 DOI: 10.1042/BCJ20210548] [Reference Citation Analysis]
71 Li R, Zhao W, Liang R, Jin C, Xiong H. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma. Front Mol Biosci 2022;9:917839. [DOI: 10.3389/fmolb.2022.917839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Pan Y, Liao X, Yang L, Zhang C, Wang J, Zheng P, Yu G, Song H. Extract of Marsdenia tenacissima (Roxb.) Moon [Apocynaceae] Suppresses Hepatocellular Carcinoma by Inhibiting Angiogenesis. Front Pharmacol 2022;13:900128. [DOI: 10.3389/fphar.2022.900128] [Reference Citation Analysis]
73 Sheng J, Lv E, Xia L, Huang W. Emerging roles and potential clinical applications of long non-coding RNAs in hepatocellular carcinoma. Biomed Pharmacother 2022;153:113327. [PMID: 35779423 DOI: 10.1016/j.biopha.2022.113327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Mao D, Xu M, Jiang Q, Sun H, Sun F, Yang R, Chai Y, Li X, Li B, Li Y. A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma. Front Pharmacol 2022;13:951831. [DOI: 10.3389/fphar.2022.951831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Temraz S, Nasr R, Mukherji D, Kreidieh F, Shamseddine A. Liquid Biopsy Derived Circulating Tumor Cells and Circulating Tumor DNA as Novel Biomarkers in Hepatocellular Carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35758097 DOI: 10.1080/14737159.2022.2094706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Guo L, Jia L, Luo L, Xu X, Xiang Y, Ren Y, Ren D, Shen L, Liang T. Critical Roles of Circular RNA in Tumor Metastasis via Acting as a Sponge of miRNA/isomiR. IJMS 2022;23:7024. [DOI: 10.3390/ijms23137024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Assante G, Chandrasekaran S, Ng S, Tourna A, Chung CH, Isse KA, Banks JL, Soffientini U, Filippi C, Dhawan A, Liu M, Rozen SG, Hoare M, Campbell P, Ballard JWO, Turner N, Morris MJ, Chokshi S, Youngson NA. Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease. Genome Med 2022;14:67. [PMID: 35739588 DOI: 10.1186/s13073-022-01071-5] [Reference Citation Analysis]
78 Kubina R, Krzykawski K, Kabała-dzik A, Wojtyczka RD, Chodurek E, Dziedzic A. Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review. Nutrients 2022;14:2604. [DOI: 10.3390/nu14132604] [Reference Citation Analysis]
79 Hucke F, Pinter M, Hucke M, Bota S, Bolf D, Hackl M, Peck-radosavljevic M. Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018. Cancers 2022;14:3093. [DOI: 10.3390/cancers14133093] [Reference Citation Analysis]
80 Liu H, Yang XL, Dong ZR, Chen ZQ, Hong JG, Wang DX, Li T. Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022. [PMID: 35722709 DOI: 10.1111/jgh.15915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Bomberna T, Vermijs S, Lejoly M, Verslype C, Bonne L, Maleux G, Debbaut C. A Hybrid Particle-Flow CFD Modeling Approach in Truncated Hepatic Arterial Trees for Liver Radioembolization: A Patient-specific Case Study. Front Bioeng Biotechnol 2022;10:914979. [PMID: 35711632 DOI: 10.3389/fbioe.2022.914979] [Reference Citation Analysis]
82 Zhao Z, Zheng Z, Huang J, Wang J, Peng T, Lin Y, Jian Z. Expression of ALG3 in Hepatocellular Carcinoma and Its Clinical Implication. Front Mol Biosci 2022;9:816102. [DOI: 10.3389/fmolb.2022.816102] [Reference Citation Analysis]
83 Badami E, Busà R, Douradinha B, Russelli G, Miceli V, Gallo A, Zito G, Conaldi PG, Iannolo G. Hepatocellular carcinoma, hepatitis C virus infection and miRNA involvement: Perspectives for new therapeutic approaches. World J Gastroenterol 2022; 28(22): 2417-2428 [DOI: 10.3748/wjg.v28.i22.2417] [Reference Citation Analysis]
84 Xing QQ, Li JM, Dong X, Zeng DY, Chen ZJ, Lin XY, Pan JS. Socioeconomics and attributable etiology of primary liver cancer, 1990-2019. World J Gastroenterol 2022; 28(21): 2361-2382 [DOI: 10.3748/wjg.v28.i21.2361] [Reference Citation Analysis]
85 Deng Y, Huang J, Wong MCS. Associations between six dietary habits and risk of hepatocellular carcinoma: A Mendelian randomization study. Hepatol Commun 2022. [PMID: 35670026 DOI: 10.1002/hep4.1960] [Reference Citation Analysis]
86 Psaraki A, Ntari L, Karakostas C, Korrou-Karava D, Roubelakis MG. Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases. Hepatology 2022;75:1590-603. [PMID: 34449901 DOI: 10.1002/hep.32129] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
87 Chen X, Li M, Guo R, Liu W, Li J, Zong X, Chen Q, Wang J. The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdom Radiol (NY) 2022;47:2057-70. [PMID: 35312822 DOI: 10.1007/s00261-022-03484-7] [Reference Citation Analysis]
88 Yang A, Wu Q, Chen Q, Yang J, Li H, Tao Y, Wang A, Sun Y, Zhang J. Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase. Chemico-Biological Interactions 2022;360:109938. [DOI: 10.1016/j.cbi.2022.109938] [Reference Citation Analysis]
89 Yang L, Zou T, Chen Y, Zhao Y, Wu X, Li M, Du F, Chen Y, Xiao Z, Shen J. Hepatitis B virus X protein mediated epigenetic alterations in the pathogenesis of hepatocellular carcinoma. Hepatol Int 2022. [PMID: 35648301 DOI: 10.1007/s12072-022-10351-6] [Reference Citation Analysis]
90 Canillas L, Parcerisa M, Coll S, García-retortillo M, Macià F, Bessa X, Castells X, Puigvehí M, Posso M. Prevalence and characteristics of hepatitis C virus-related hepatocellular carcinoma in a Spanish university hospital. Cancer Epidemiology 2022;78:102142. [DOI: 10.1016/j.canep.2022.102142] [Reference Citation Analysis]
91 Ren Y, Li S, Song Z, Luo Q, Zhang Y, Wang H. The Regulatory Roles of Polysaccharides and Ferroptosis-Related Phytochemicals in Liver Diseases. Nutrients 2022;14:2303. [PMID: 35684103 DOI: 10.3390/nu14112303] [Reference Citation Analysis]
92 Lin Z, Huang X, Ji X, Tian N, Gan Y, Ke L. Analysis of multiple databases identifies crucial genes correlated with prognosis of hepatocellular carcinoma. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-13159-4] [Reference Citation Analysis]
93 Hyams TC, Luo L, Hair B, Lee K, Lu Z, Seminara D. Machine Learning Approach to Facilitate Knowledge Synthesis at the Intersection of Liver Cancer, Epidemiology, and Health Disparities Research. JCO Clin Cancer Inform 2022;6:e2100129. [PMID: 35623021 DOI: 10.1200/CCI.21.00129] [Reference Citation Analysis]
94 Sun J, Wang J, Li T, Ma Y, Xue D, Chen J. Design and synthesis of ludartin derivatives as potential anticancer agents against hepatocellular carcinoma. Med Chem Res. [DOI: 10.1007/s00044-022-02890-2] [Reference Citation Analysis]
95 Yu J, Gao G, Wang J, Zhao J, Zhang Y, Jiang D, Huang F, Tang M. Value of 5-Hydroxymethylcytosine in HBV-Carrying High-Risk Hepatocellular Carcinoma Population: An Evaluation Based on Differential Analysis. Computational and Mathematical Methods in Medicine 2022;2022:1-7. [DOI: 10.1155/2022/4835417] [Reference Citation Analysis]
96 Huang K, Lee P, Chao Y, Su C, Lee I, Lan K, Chu C, Hung Y, Chen S, Hou M, Huang Y. Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:175883592210994. [DOI: 10.1177/17588359221099401] [Reference Citation Analysis]
97 Guan MC, Ouyang W, Liu SY, Sun LY, Chen WY, Tong XM, Zhu H, Yang T. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00121-7. [PMID: 35643910 DOI: 10.1016/j.hbpd.2022.05.003] [Reference Citation Analysis]
98 Wu Y, Xu X, Liu M, Qin X, Wu Q, Ding H, Zhao Q. DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis. Biochem Pharmacol 2022;:115093. [PMID: 35580648 DOI: 10.1016/j.bcp.2022.115093] [Reference Citation Analysis]
99 Kong W, Mao Z, Han C, Ding Z, Yuan Q, Zhang G, Li C, Wu X, Chen J, Guo M, Hong S, Yu F, Liu R, Wang X, Zhang J. A Novel Epithelial-Mesenchymal Transition Gene Signature Correlated With Prognosis, and Immune Infiltration in Hepatocellular Carcinoma. Front Pharmacol 2022;13:863750. [PMID: 35517787 DOI: 10.3389/fphar.2022.863750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Choi SI, Cho Y, Ki M, Kim BH, Lee IJ, Kim TH, Kim SH, Koh YH, Kim HB, Hong EK, Kim CM, Park JW. Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts. PLoS One 2022;17:e0265668. [PMID: 35324973 DOI: 10.1371/journal.pone.0265668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 Pang S, Shi Y, Xu D, Sun Z, Chen Y, Yang Y, Zhao X, Si-Ma H, Yang N. Screening of Hepatocellular Carcinoma Patients with High Risk of Early Recurrence After Radical Hepatectomy Using a Nomogram Model Based on the γ-Glutamyl Transpeptidase-to-Albumin Ratio. J Gastrointest Surg 2022. [PMID: 35508683 DOI: 10.1007/s11605-022-05326-9] [Reference Citation Analysis]
102 Shen H, Yu H, Li QY, Wei YT, Fu J, Dong H, Cao D, Guo LN, Chen L, Yang Y, Xu Y, Wu MC, Wang HY, Chen Y. Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells. Acta Pharmacol Sin 2022. [PMID: 35508720 DOI: 10.1038/s41401-022-00907-5] [Reference Citation Analysis]
103 Zhu D, Fang C, Yang Z, Ren Y, Yang F, Zheng S, Jiang M, Miao X, Liu D, Chen B, Yao X, Chen Y. Tubulin-binding peptide RR-171 derived from human umbilical cord serum displays antitumor activity against hepatocellular carcinoma via inducing apoptosis and activating the NF-kappa B pathway. Cell Prolif 2022;:e13241. [PMID: 35504605 DOI: 10.1111/cpr.13241] [Reference Citation Analysis]
104 Duberg AS, Lybeck C, Fält A, Montgomery S, Aleman S. Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: A national register study. Hepatol Commun 2022. [PMID: 35503810 DOI: 10.1002/hep4.1974] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV. Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology 2022;75:1257-74. [PMID: 34918361 DOI: 10.1002/hep.32241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
106 Wan J, Wang B, Wu M, Li J, Gong R, Song L, Zhang H, Zhu G, Chen S, Cai J, Xing X, Wang Y, Yang Y, Cai C, Huang R, Liu H, Dai Z. MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215750] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Rayman S, Sucandy I, Ross SB, Crespo K, Syblis C, App S, Rosemurgy A. Does Metabolic Syndrome Effect the Perioperative Course and Costs of Patients with Hepatocellular Carcinoma Undergoing Robotic Hepatectomy? A Propensity Score-Matched Analysis. Am Surg 2022;:31348221091476. [PMID: 35477309 DOI: 10.1177/00031348221091476] [Reference Citation Analysis]
108 Dakua SP, Nayak A. A review on treatments of hepatocellular carcinoma—role of radio wave ablation and possible improvements. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00191-2] [Reference Citation Analysis]
109 Bae BK, Park HC, Yoo GS, Choi MS, Oh JH, Yu JI. The Significance of Systemic Inflammation Markers in Intrahepatic Recurrence of Early-Stage Hepatocellular Carcinoma after Curative Treatment. Cancers 2022;14:2081. [DOI: 10.3390/cancers14092081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Peschl V, Seitz T, Sommer J, Thasler W, Bosserhoff A, Hellerbrand C. Bone morphogenetic protein 13 in hepatic stellate cells and hepatic fibrosis. J Cell Biochem 2022. [PMID: 35442524 DOI: 10.1002/jcb.30248] [Reference Citation Analysis]
111 Liu Y, Xia H, Li M, Chen Y, Zhou W, Chen Y, Wu Y, Ali L. Overexpressed RING Finger 44 Correlates with Poor Prognosis in Hepatocellular Carcinoma. Journal of Healthcare Engineering 2022;2022:1-18. [DOI: 10.1155/2022/3522866] [Reference Citation Analysis]
112 Nevola R, Messina V, Marrone A, Coppola N, Rescigno C, Esposito V, Sangiovanni V, Claar E, Pisaturo M, Fusco FM, Rosario P, Izzi A, Pisapia R, Rosato V, Maggi P, Adinolfi LE. Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic-Standardized National Screening or One Tailored to Local Epidemiology? Biology (Basel) 2022;11:609. [PMID: 35453808 DOI: 10.3390/biology11040609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
113 Deng J, Wen F. Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate-Stage Hepatocellular Carcinoma, What Else Can We Do? Front Oncol 2022;12:824799. [PMID: 35425716 DOI: 10.3389/fonc.2022.824799] [Reference Citation Analysis]
114 Machairas N, Tsilimigras DI, Pawlik TM. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers 2022;14:2018. [DOI: 10.3390/cancers14082018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
115 Leyh C, Ehmer U, Roessler D, Philipp AB, Reiter FP, Jeliazkova P, Jochheim LS, Jeschke M, Hammig J, Ludwig JM, Theysohn JM, Geier A, Lange CM. Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis. Cancers (Basel) 2022;14:1975. [PMID: 35454881 DOI: 10.3390/cancers14081975] [Reference Citation Analysis]
116 Wang C, Zhu K, Shi P, Ding X, Zhang S. Rapid and label-free detection of aflatoxin B1 using a rationally truncated aptamer and via circular dichroism measurement. Chem Commun (Camb) 2022;58:4779-82. [PMID: 35343550 DOI: 10.1039/d2cc00078d] [Reference Citation Analysis]
117 Manzar GS, De BS, Abana CO, Lee SS, Javle M, Kaseb AO, Vauthey J, Tran Cao HS, Koong AC, Smith GL, Taniguchi CM, Holliday EB, Das P, Koay EJ, Ludmir EB. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers 2022;14:1901. [DOI: 10.3390/cancers14081901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
118 Zhang S, Zhao H, Chen Y, Zhang Y, Zhong WL. GNL3 Regulates SIRT1 Transcription and Promotes Hepatocellular Carcinoma Stem Cell-Like Features and Metastasis. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/1555670] [Reference Citation Analysis]
119 Jacobson IM, Brown RS Jr, McMahon BJ, Perrillo RP, Gish R. An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus. J Clin Gastroenterol 2022. [PMID: 35389923 DOI: 10.1097/MCG.0000000000001695] [Reference Citation Analysis]
120 Xiong KG, Ke KY, Chen LF, Kong JF, Lin TS, Lin QB, Lin S, Zhu YY. The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00051-0. [PMID: 35466065 DOI: 10.1016/j.hbpd.2022.04.001] [Reference Citation Analysis]
121 Dai Y, Jiang H, Feng S, Xia Y, Li J, Zhao S, Wang D, Zeng X, Chen Y, Xin Y, Liu D. Noninvasive Imaging Evaluation Based on Computed Tomography of the Efficacy of Initial Transarterial Chemoembolization to Predict Outcome in Patients with Hepatocellular Carcinoma. JHC 2022;Volume 9:273-88. [DOI: 10.2147/jhc.s351077] [Reference Citation Analysis]
122 Chen L, Tao X, Zhao Y, Zeng M, Mi Y, Xu L. Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. Aliment Pharmacol Ther 2022;55:1059-60. [PMID: 35362130 DOI: 10.1111/apt.16834] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Hsueh R, Wu W, Lin C, Liu C, Huang Y, Hu J, Wu C, Sung F, Liu W, Yu M. Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroclearance in Chronic Hepatitis B. JHC 2022;Volume 9:301-13. [DOI: 10.2147/jhc.s355540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Lai X, Wu Y, Hong G, Li J, Luo Q, Yuan J, Dai G, Liu S, Feng H, Wang F. A Novel Gene Signature Based on CDC20 and FCN3 for Prediction of Prognosis and Immune Features in Patients with Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-15. [DOI: 10.1155/2022/9117205] [Reference Citation Analysis]
125 Zhou Y, Jia K, Wang S, Li Z, Li Y, Lu S, Yang Y, Zhang L, Wang M, Dong Y, Zhang L, Zhang W, Li N, Yu Y, Cao X, Hou J. Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7-acetylated and cytoplasm-translocated G protein GαS. Hepatology 2022. [PMID: 35344606 DOI: 10.1002/hep.32487] [Reference Citation Analysis]
126 Liu Y, Al-Adra DP, Lan R, Jung G, Li H, Yeh MM, Liu YZ. RNA sequencing analysis of hepatocellular carcinoma identified oxidative phosphorylation as a major pathologic feature. Hepatol Commun 2022. [PMID: 35344307 DOI: 10.1002/hep4.1945] [Reference Citation Analysis]
127 Dolicka D, Zahoran S, Correia de Sousa M, Gjorgjieva M, Sempoux C, Fournier M, Maeder C, Collart MA, Foti M, Sobolewski C. TIA1 Loss Exacerbates Fatty Liver Disease but Exerts a Dual Role in Hepatocarcinogenesis. Cancers 2022;14:1704. [DOI: 10.3390/cancers14071704] [Reference Citation Analysis]
128 Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing Epidemiology of Hepatocellular Carcinoma in Asia. Liver Int 2022. [PMID: 35319165 DOI: 10.1111/liv.15251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
129 Chen X, Wang Z, Zhao X, Zhang L, Zhou L, Li X, Ge C, Zhao F, Chen T, Xie H, Cui Y, Tian H, Li H, Yao M, Li J. STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1. Oncogene 2022. [PMID: 35314791 DOI: 10.1038/s41388-022-02273-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Chen Y, Du F, Tang L, Xu J, Zhao Y, Wu X, Li M, Shen J, Wen Q, Cho CH, Xiao Z. Carboranes as unique pharmacophores in antitumor medicinal chemistry. Mol Ther Oncolytics 2022;24:400-16. [PMID: 35141397 DOI: 10.1016/j.omto.2022.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
131 Wong CS, Lim CW, Mohammed HI, Liew KY, Tham CL, Tan JW, Chee HY. Current Perspective of Plant-Based Diets on Communicable Diseases Caused by Viruses: A Mini Review. Front Nutr 2022;9:786972. [DOI: 10.3389/fnut.2022.786972] [Reference Citation Analysis]
132 Yang J, Wang J, Li H, Gao S, Fan Y, Wang K. IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Front Oncol 2022;12:746643. [DOI: 10.3389/fonc.2022.746643] [Reference Citation Analysis]
133 He F, Chen G, He R, Huang Z, Li J, Wu W, Chen J, Tang Y, Li D, Pan S, Feng Z, Dang Y. Expression of IER3 in hepatocellular carcinoma: clinicopathology, prognosis, and potential regulatory pathways. PeerJ 2022;10:e12944. [DOI: 10.7717/peerj.12944] [Reference Citation Analysis]
134 Kweon SM, Kim G, Jeong Y, Huang W, Lee JS, Lai KKY. Midnolin Regulates Liver Cancer Cell Growth In Vitro and In Vivo. Cancers (Basel) 2022;14:1421. [PMID: 35326575 DOI: 10.3390/cancers14061421] [Reference Citation Analysis]
135 Soong RS, Chen YC, Chou TC, Chiang PH, Chen WM, Chiang MF, Shia BC, Wu SY. A Novel Predictive Scoring System for 90-Day Mortality among Patients with Hepatocellular Cell Carcinoma Receiving Major Hepatectomy. Cancers (Basel) 2022;14:1398. [PMID: 35326550 DOI: 10.3390/cancers14061398] [Reference Citation Analysis]
136 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 Li W, Pei S, Zhang X, Qi D, Zhang W, Dou Y, Yang R, Yao X, Zhang Z, Xie S, Fang D, Sun H. Cinobufotalin inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells through down-regulate β-catenin in vitro and in vivo. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174886] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Ram AK, Vairappan B, Srinivas BH. Nimbolide attenuates gut dysbiosis and prevents bacterial translocation by improving intestinal barrier integrity and ameliorating inflammation in hepatocellular carcinoma. Phytotherapy Research. [DOI: 10.1002/ptr.7434] [Reference Citation Analysis]
139 Elena Laino M, Viganò L, Ammirabile A, Lofino L, Generali E, Francone M, Lleo A, Saba L, Savevski V. The added value of Artificial Intelligence to LI-RADS categorization: a systematic review. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
140 Stepanova M, Kabbara K, Mohess D, Verma M, Roche‐green A, Alqahtani S, Ong J, Burra P, Younossi ZM. Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients. Hepatology Communications. [DOI: 10.1002/hep4.1915] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Chen T, Liu J, Li Y, Wei S. Burden of Disease Associated with Dietary Exposure to Aflatoxins in China in 2020. Nutrients 2022;14:1027. [PMID: 35268003 DOI: 10.3390/nu14051027] [Reference Citation Analysis]
142 She S, Ren L, Chen P, Wang M, Chen D, Wang Y, Chen H. Functional Roles of Chemokine Receptor CCR2 and Its Ligands in Liver Disease. Front Immunol 2022;13:812431. [DOI: 10.3389/fimmu.2022.812431] [Reference Citation Analysis]
143 Talebi AS, Rajabi H, Watabe H. Role of nanoparticles in transarterial radioembolization with glass microspheres. Ann Nucl Med 2022. [PMID: 35199286 DOI: 10.1007/s12149-022-01727-7] [Reference Citation Analysis]
144 Zhang J, Liu Z, Liu L, Huang M, Huang Y. Th22/IL-22 mediates the progression of HBV-related hepatocellular carcinoma via STAT3. Cytotechnology. [DOI: 10.1007/s10616-021-00517-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Lin YP, Wang PM, Chuang CH, Yong CC, Liu YW, Huang PY, Yao CC, Tsai MC. Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study. Front Oncol 2022;12:816472. [PMID: 35186751 DOI: 10.3389/fonc.2022.816472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Chen Y, Fan Z, Hu S, Lu C, Xiang Y, Liao S. Ferroptosis: A New Strategy for Cancer Therapy. Front Oncol 2022;12:830561. [DOI: 10.3389/fonc.2022.830561] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
147 Luo Z, Zou Y, Xie J, Cao H, Chen Y, Ding Y, Li X, Deng Y, Wu L. Influence of Demographic Factors on Long-Term Trends of Premature Mortality and Burden Due to Liver Cancer: Findings From a Population-Based Study in Shanghai, China, 1973–2019. Front Public Health 2022;10:808917. [DOI: 10.3389/fpubh.2022.808917] [Reference Citation Analysis]
148 Kusnick J, Bruneau A, Tacke F, Hammerich L. Ferroptosis in Cancer Immunotherapy—Implications for Hepatocellular Carcinoma. Immuno 2022;2:185-217. [DOI: 10.3390/immuno2010014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Zheng P, Huang Z, Tong DC, Zhou Q, Tian S, Chen BW, Ning DM, Guo YM, Zhu WH, Long Y, Xiao W, Deng Z, Lei YC, Tian XF. Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol 2022; 14(2): 450-477 [DOI: 10.4251/wjgo.v14.i2.450] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
150 Wang Y, Miao X, Jiang Y, Wu Z, Zhu X, Liu H, Wu X, Cai J, Ding X, Gong W. The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma. Cell Death Dis 2022;13:146. [PMID: 35165269 DOI: 10.1038/s41419-022-04583-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
151 Reyes-avendaño I, Reyes-jiménez E, González-garcía K, Pérez-figueroa DC, Baltiérrez-hoyos R, Tapia-pastrana G, Sánchez-chino XM, Villa-treviño S, Arellanes-robledo J, Vásquez-garzón VR. Quercetin Regulates Key Components of the Cellular Microenvironment during Early Hepatocarcinogenesis. Antioxidants 2022;11:358. [DOI: 10.3390/antiox11020358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
152 Wang C, Gao N, Yang L, Guo Y, Fang Y, Wang T, Xu C, Li GF, Zhou J, Zhang Y, Wen Q, Qiao H. Stat4 rs7574865 polymorphism promotes the occurrence and progression of hepatocellular carcinoma via the Stat4/CYP2E1/FGL2 pathway. Cell Death Dis 2022;13:130. [PMID: 35136014 DOI: 10.1038/s41419-022-04584-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Alvarez CS, Petrick JL, Parisi D, McMahon BJ, Graubard BI, McGlynn KA. Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992-2018. Hepatology 2022. [PMID: 35124828 DOI: 10.1002/hep.32394] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
154 Dong Y, Liu X, Jiang B, Wei S, Xiang B, Liao R, Wang Q, He X. A Genome-Wide Investigation of Effects of Aberrant DNA Methylation on the Usage of Alternative Promoters in Hepatocellular Carcinoma. Front Oncol 2021;11:780266. [PMID: 35111672 DOI: 10.3389/fonc.2021.780266] [Reference Citation Analysis]
155 Guo Y, Wu G, Yi J, Yang Q, Jiang W, Lin S, Yang X, Cai X, Mao L. Anti-Hepatocellular Carcinoma Effect and Molecular Mechanism of the Estrogen Signaling Pathway. Front Oncol 2021;11:763539. [PMID: 35096574 DOI: 10.3389/fonc.2021.763539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
156 Groopman JD, Smith JW, Rivera-Andrade A, Alvarez CS, Kroker-Lobos MF, Egner PA, Gharzouzi E, Dean M, McGlynn KA, Ramírez-Zea M. Aflatoxin and the Etiology of Liver Cancer and Its Implications for Guatemala. World Mycotoxin J 2021;14:305-17. [PMID: 35096197 DOI: 10.3920/wmj2020.2641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
157 Meister FA, Lurje G, Verhoeven S, Wiltberger G, Heij L, Liu WJ, Jiang D, Bruners P, Lang SA, Ulmer TF, Neumann UP, Bednarsch J, Czigany Z. The Role of Sarcopenia and Myosteatosis in Short- and Long-Term Outcomes Following Curative-Intent Surgery for Hepatocellular Carcinoma in a European Cohort. Cancers (Basel) 2022;14:720. [PMID: 35158988 DOI: 10.3390/cancers14030720] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
158 Śmiech M, Leszczyński P, Wardell C, Poznański P, Pierzchała M, Taniguchi H. Oncogenic Mutation BRAF V600E Changes Phenotypic Behavior of THLE-2 Liver Cells through Alteration of Gene Expression. Int J Mol Sci 2022;23:1548. [PMID: 35163468 DOI: 10.3390/ijms23031548] [Reference Citation Analysis]
159 Wang J, Pillai AA. Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma? Aliment Pharmacol Ther 2022;55:479-80. [DOI: 10.1111/apt.16732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Cao L, Han Y, Wang Y, Pei L, Yue Z, Qin L, Liu B, Cui J, Jia M, Wang H. Metabolic Profiling Identified a Novel Biomarker Panel for Metabolic Syndrome-Positive Hepatocellular Cancer. Front Endocrinol 2022;12:816748. [DOI: 10.3389/fendo.2021.816748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Cucarull B, Tutusaus A, Rider P, Hernáez-Alsina T, Cuño C, García de Frutos P, Colell A, Marí M, Morales A. Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers (Basel) 2022;14:621. [PMID: 35158892 DOI: 10.3390/cancers14030621] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
162 Yang R, Yin N, Zhao Y, Li D, Zhang X, Li X, Zhang Y, Faiola F. Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System. Front Pharmacol 2021;12:772768. [PMID: 35046808 DOI: 10.3389/fphar.2021.772768] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
163 Zhang Y, Qin P, Xu X, Li M, Huang H, Yan J, Zhou Y. Mediator Complex Subunit 19 Promotes the Development of Hepatocellular Carcinoma by Regulating the AKT/mTOR Signaling Pathway. Front Oncol 2021;11:792285. [PMID: 35047403 DOI: 10.3389/fonc.2021.792285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Chen Y, Shang H, Wang C, Zeng J, Zhang S, Wu B, Cheng W. RNA-Seq Explores the Mechanism of Oxygen-Boosted Sonodynamic Therapy Based on All-in-One Nanobubbles to Enhance Ferroptosis for the Treatment of HCC. Int J Nanomedicine 2022;17:105-23. [PMID: 35027829 DOI: 10.2147/IJN.S343361] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
165 Silverman RB. Inactivators of Ornithine Aminotransferase for the Treatment of Hepatocellular Carcinoma. ACS Med Chem Lett 2022;13:38-49. [PMID: 35059122 DOI: 10.1021/acsmedchemlett.1c00526] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 He T, Chen T, Liu X, Zhang B, Yue S, Cao J, Zhang G. A Web-Based Prediction Model for Cancer-Specific Survival of Elderly Patients With Early Hepatocellular Carcinoma: A Study Based on SEER Database. Front Public Health 2022;9:789026. [DOI: 10.3389/fpubh.2021.789026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Wang Q, Xie H, Peng H, Yan J, Han L, Ye G. ZC3H13 Inhibits the Progression of Hepatocellular Carcinoma through m6A-PKM2-Mediated Glycolysis and Enhances Chemosensitivity. J Oncol 2021;2021:1328444. [PMID: 35003256 DOI: 10.1155/2021/1328444] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
168 Chen Z, Zou Y, Zhang Y, Chen Z, Wu F, Jin H, Shi N, Rai SN. A Pyroptosis-Based Prognostic Model for Immune Microenvironment Estimation of Hepatocellular Carcinoma. Disease Markers 2022;2022:1-17. [DOI: 10.1155/2022/8109771] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
169 Tian F, Cai D. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma. Gene 2022;807:145964. [PMID: 34530087 DOI: 10.1016/j.gene.2021.145964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Li X, Han M, Zhang H, Liu F, Pan Y, Zhu J, Liao Z, Chen X, Zhang B. Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma. Biomark Res 2022;10:2. [PMID: 35000617 DOI: 10.1186/s40364-021-00345-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Liao Y, Li L, Liu H, Song Y. High Expression of Ubiquitin-Specific Protease 39 and Its Roles in Prognosis in Patients with Hepatocellular Carcinoma. Evid Based Complement Alternat Med 2021;2021:6233175. [PMID: 34987596 DOI: 10.1155/2021/6233175] [Reference Citation Analysis]
172 Spiegelberg J, Iken T, Diener MK, Fichtner-Feigl S. Robotic-Assisted Surgery for Primary Hepatobiliary Tumors-Possibilities and Limitations. Cancers (Basel) 2022;14:265. [PMID: 35053429 DOI: 10.3390/cancers14020265] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
173 Yang J, Pan G, Guan L, Liu Z, Wu Y, Liu Z, Lu W, Li S, Xu H, Ouyang G. The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels. Cancer Med 2022. [PMID: 34989144 DOI: 10.1002/cam4.4530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
174 Abbas EAER, Barakat AB, Hassany M, Youssef SS. The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients. J Genet Eng Biotechnol 2022;20:4. [PMID: 34978646 DOI: 10.1186/s43141-021-00282-4] [Reference Citation Analysis]
175 Maddah R, Shariati P, Arabpour J, Bazireh H, Shadpirouz M, Kafraj AS. Identification of critical genes and pathways associated with hepatocellular carcinoma and type 2 diabetes mellitus using integrated bioinformatics analysis. Informatics in Medicine Unlocked 2022;30:100956. [DOI: 10.1016/j.imu.2022.100956] [Reference Citation Analysis]
176 Hu J, Albadawi H, Zhang Z, Salomao MA, Gunduz S, Rehman S, D'Amone L, Mayer JL, Omenetto F, Oklu R. Silk Embolic Material for Catheter-Directed Endovascular Drug Delivery. Adv Mater 2022;34:e2106865. [PMID: 34695275 DOI: 10.1002/adma.202106865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
177 Harkus U, Wankell M, Palamuthusingam P, Mcfarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
178 Polikoff A, Wessner CE, Balasubramanya R, Dulka S, Liu JB, Machado P, Savsani E, Lyshchik A, Shaw CM, Eisenbrey JR. Imaging appearance of residual HCC following incomplete trans-arterial chemoembolization on contrast-enhanced imaging. Abdom Radiol (NY) 2022;47:152-60. [PMID: 34643782 DOI: 10.1007/s00261-021-03298-z] [Reference Citation Analysis]
179 Vitale G, Gitto S, Campani C, Turco L, Baldan A, Marra F, Morelli MC. Biological therapies in patients with liver disease: are they really lifesavers? Expert Opin Biol Ther 2021;:1-18. [PMID: 34860629 DOI: 10.1080/14712598.2022.2013799] [Reference Citation Analysis]
180 Niu B, Wei S, Sun J, Zhao H, Wang B, Chen G. Deciphering the molecular mechanism of tetrandrine in inhibiting hepatocellular carcinoma and increasing sorafenib sensitivity by combining network pharmacology and experimental evaluation. Pharm Biol 2022;60:75-86. [PMID: 34962429 DOI: 10.1080/13880209.2021.2017468] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
181 Lin H, Zhang X, Li G, Wong GL, Wong VW. Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:972-82. [PMID: 34966660 DOI: 10.14218/JCTH.2021.00201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
182 Tang X, Liu B, Zhang C, Tang W, Liang S, Xiao Y, Deng R, Li Z. SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway. Front Oncol 2021;11:773045. [PMID: 34950583 DOI: 10.3389/fonc.2021.773045] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
183 Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
184 Mahassadi AK, Anzouan-Kacou Kissi H, Attia AK. The Prognostic Values of Neutrophil-to-lymphocyte Ratio and Platelet-to-Lymphocyte Ratio at Baseline in Predicting the In-hospital Mortality in Black African Patients with Advanced Hepatocellular Carcinoma in Palliative Treatment: A Comparative Cohort Study. Hepat Med 2021;13:123-34. [PMID: 34938131 DOI: 10.2147/HMER.S333980] [Reference Citation Analysis]
185 Chen H, Li Z, Wu F, Ji W, Lu L, Wu Z, Huang Y, Wang W, Li S. BCL10 correlates with bad prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma. IUBMB Life. [DOI: 10.1002/iub.2581] [Reference Citation Analysis]
186 Eresen A, Sun C, Zhou K, Shangguan J, Wang B, Pan L, Hu S, Ma Q, Yang J, Zhang Z, Yaghmai V. Early Differentiation of Irreversible Electroporation Ablation Regions With Radiomics Features of Conventional MRI. Acad Radiol 2021:S1076-6332(21)00559-6. [PMID: 34933803 DOI: 10.1016/j.acra.2021.11.020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
187 Wu Y, Yi M, Zhu S, Wang H, Wu K. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol 2021;10:56. [PMID: 34922633 DOI: 10.1186/s40164-021-00250-1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
188 Wang Y, Xiao X, Chen S, Huang C, Zhou J, Dai E, Li Y, Liu L, Huang X, Gao Z, Wu C, Fang M, Gao C. The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing. Front Immunol 2021;12:775461. [PMID: 34899733 DOI: 10.3389/fimmu.2021.775461] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
189 Gomez-Quiroz LE, Roman S. Influence of genetic and environmental risk factors in the development of hepatocellular carcinoma in Mexico. Ann Hepatol 2021;:100649. [PMID: 34902602 DOI: 10.1016/j.aohep.2021.100649] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Azit NA, Sahran S, Voon Meng L, Subramaniam M, Mokhtar S, Mohammed Nawi A. Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country. PLoS One 2021;16:e0260675. [PMID: 34882716 DOI: 10.1371/journal.pone.0260675] [Reference Citation Analysis]
191 Men H, Young JL, Zhou W, Zhang H, Wang X, Xu J, Lin Q, Tan Y, Zheng Y, Cai L. Early-Life Exposure to Low-Dose Cadmium Accelerates Diethylnitrosamine and Diet-Induced Liver Cancer. Oxid Med Cell Longev 2021;2021:1427787. [PMID: 34876963 DOI: 10.1155/2021/1427787] [Reference Citation Analysis]
192 Hasanpourghadi M, Novikov M, Newman D, Xiang Z, Zhou XY, Magowan C, Ertl HCJ. Hepatitis B virus polymerase-specific T cell epitopes shift in a mouse model of chronic infection. Virol J 2021;18:242. [PMID: 34876153 DOI: 10.1186/s12985-021-01712-y] [Reference Citation Analysis]
193 Ramos IPR, Dias ML, Nunes De Moraes AC, Meireles Ferreira FG, Souza SAL, Gutfilen B, Barboza T, Ferreira Pimentel C, Paz Batista CM, Kasai-Brunswick TH, Fortes FDSA, De Andrade CBV, Goldenberg RCDS. Granulocyte Colony-Stimulating Factor Treatment Before Radiotherapy Protects Against Radiation-Induced Liver Disease in Mice. Front Pharmacol 2021;12:725084. [PMID: 34867327 DOI: 10.3389/fphar.2021.725084] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
194 Zhou F, Sun X. Cholesterol Metabolism: A Double-Edged Sword in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:762828. [PMID: 34869352 DOI: 10.3389/fcell.2021.762828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
195 Campani C, Capone M, Liotta F, Arena U, Adotti V, Di Bonaventura C, Aburas S, Colagrande S, Calistri L, Annunziato F, Marra F. Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma. Dig Liver Dis 2021:S1590-8658(21)00850-1. [PMID: 34876355 DOI: 10.1016/j.dld.2021.11.010] [Reference Citation Analysis]
196 De Battista D, Zamboni F, Gerstein H, Sato S, Markowitz TE, Lack J, Engle RE, Farci P. Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC. J Hepatocell Carcinoma 2021;8:1399-413. [PMID: 34849372 DOI: 10.2147/JHC.S325959] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
197 Gao L, Yan H, Zhu S, Wang X, Tan Y, Du J, Feng D, Zhang H, Gu Z. Targeted delivery of Bi2Se3 Nanoflowers to orthotopic liver tumor via transarterial infusion for enhanced microwave ablation sensibilization. Nano Today 2021;41:101314. [DOI: 10.1016/j.nantod.2021.101314] [Reference Citation Analysis]
198 Filippi L, Braat AJ. Theragnostics in primary and secondary liver tumors: the need for a personalized approach. Q J Nucl Med Mol Imaging 2021;65:353-70. [PMID: 34881847 DOI: 10.23736/S1824-4785.21.03407-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
199 Aydin Y, Koksal AR, Thevenot P, Chava S, Heidari Z, Lin D, Sandow T, Moroz K, Parsi MA, Scott J, Cohen A, Dash S. Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis. JHC 2021;Volume 8:1579-96. [DOI: 10.2147/jhc.s327339] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
200 Abdelhamid AM, Saber S, Youssef ME, Gaafar AGA, Eissa H, Abd-Eldayem MA, Alqarni M, Batiha GE, Obaidullah AJ, Shahien MA, El-Ahwany E, Amin NA, Etman MA, Kaddah MMY, Abd El-Fattah EE. Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application. Biomed Pharmacother 2022;145:112455. [PMID: 34844106 DOI: 10.1016/j.biopha.2021.112455] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
201 Fu C, Li J, Li P, Cheng D. LncRNA DNAJC3-AS1 Promotes Hepatocellular Carcinoma (HCC) Progression via Sponging Premature miR-27b. Cancer Manag Res 2021;13:8575-83. [PMID: 34815712 DOI: 10.2147/CMAR.S321111] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
202 Deng W, Chen F, Zhou Z, Huang Y, Lin J, Zhang F, Xiao G, Liu C, Liu C, Xu L. Hepatitis B Virus Promotes Hepatocellular Carcinoma Progression Synergistically With Hepatic Stellate Cells via Facilitating the Expression and Secretion of ENPP2. Front Mol Biosci 2021;8:745990. [PMID: 34805271 DOI: 10.3389/fmolb.2021.745990] [Reference Citation Analysis]
203 Grgurevic I, Bozin T, Mikus M, Kukla M, O'Beirne J. Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers (Basel) 2021;13:5844. [PMID: 34830997 DOI: 10.3390/cancers13225844] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
204 Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01258-1. [PMID: 34813942 DOI: 10.1016/j.cgh.2021.11.020] [Reference Citation Analysis]
205 Liu Y, Duan C, Dai R, Zeng Y. Ferroptosis-mediated Crosstalk in the Tumor Microenvironment Implicated in Cancer Progression and Therapy. Front Cell Dev Biol 2021;9:739392. [PMID: 34796174 DOI: 10.3389/fcell.2021.739392] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
206 Liu DS, Frampton AE. Plasma extracellular vesicles contain unannotated small RNA clusters suitable as biomarkers for detecting early hepatocellular carcinoma. Gut 2021:gutjnl-2021-325798. [PMID: 34799372 DOI: 10.1136/gutjnl-2021-325798] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
207 Tian T, Xiao F, Li H, Ding D, Dong W, Hou G, Zhao L, Yang Y, Yang Y, Zhou W. Association between serum iron status and primary liver cancer risk: a Mendelian randomization analysis. Ann Transl Med 2021;9:1533. [PMID: 34790739 DOI: 10.21037/atm-21-4608] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
208 Kitsou K, Iliopoulou M, Spoulou V, Lagiou P, Magiorkinis G. Viral Causality of Human Cancer and Potential Roles of Human Endogenous Retroviruses in the Multi-Omics Era: An Evolutionary Epidemiology Review. Front Oncol 2021;11:687631. [PMID: 34778024 DOI: 10.3389/fonc.2021.687631] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Yang ZC, Luo MJ, Liu LL, Cai MY, Liang YJ, Chen QY, Tang LQ, Mai HQ. Alpha-fetoprotein-producing recurrent nasopharyngeal carcinoma: A case report. SAGE Open Med Case Rep 2021;9:2050313X211057704. [PMID: 34777811 DOI: 10.1177/2050313X211057704] [Reference Citation Analysis]
210 Abdelhamid AM, Selim A, Zaafan MA. The Hepatoprotective Effect of Piperine Against Thioacetamide-Induced Liver Fibrosis in Mice: The Involvement of miR-17 and TGF-β/Smads Pathways. Front Mol Biosci 2021;8:754098. [PMID: 34778375 DOI: 10.3389/fmolb.2021.754098] [Reference Citation Analysis]
211 Goto RL, Tablas MB, Prata GB, Espírito Santo SG, Fernandes AAH, Cogliati B, Barbisan LF, Romualdo GR. Vitamin D3 supplementation alleviates chemically-induced cirrhosis-associated hepatocarcinogenesis. J Steroid Biochem Mol Biol 2022;215:106022. [PMID: 34774723 DOI: 10.1016/j.jsbmb.2021.106022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
213 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
214 Wang G, Li J, Yao Y, Liu Y, Xia P, Zhang H, Yin M, Qin Z, Ma W, Yuan Y. Small nucleolar RNA 42 promotes the growth of hepatocellular carcinoma through the p53 signaling pathway. Cell Death Discov 2021;7:347. [PMID: 34759267 DOI: 10.1038/s41420-021-00740-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
215 Li J, Yu N, Li X, Cui M, Guo Q. The Single-Cell Sequencing: A Dazzling Light Shining on the Dark Corner of Cancer. Front Oncol 2021;11:759894. [PMID: 34745998 DOI: 10.3389/fonc.2021.759894] [Reference Citation Analysis]
216 Natarajan Y, El-Serag HB. Risk Factors for Hepatocellular Carcinoma: A Historical Perspective. Clin Liver Dis (Hoboken) 2021;18:1-13. [PMID: 34745580 DOI: 10.1002/cld.1042] [Reference Citation Analysis]
217 Piskin FC, Balli HT, Erdoğan KE, Sozutok S, Aikimbaev K. Whole tumor volumetric ADC analysis: relationships with histopathological differentiation of hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:5180-9. [PMID: 34415410 DOI: 10.1007/s00261-021-03240-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Nie X, Liu H, Wei X, Li L, Lan L, Fan L, Ma H, Liu L, Zhou Y, Hou R, Chen WD. miRNA-382-5p Suppresses the Expression of Farnesoid X Receptor to Promote Progression of Liver Cancer. Cancer Manag Res 2021;13:8025-35. [PMID: 34712060 DOI: 10.2147/CMAR.S324072] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
219 Yang K, Choi C, Cho H, Ahn WG, Kim SY, Shin SW, Kim Y, Jang T, Lee N, Park HC. Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models. Pharmaceutics 2021;13:1811. [PMID: 34834226 DOI: 10.3390/pharmaceutics13111811] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
220 Shen B, Sun K. Exosomal circular RNAs: A new frontier in the metastasis of digestive system tumors. Oncol Lett 2021;22:826. [PMID: 34691253 DOI: 10.3892/ol.2021.13087] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
221 Zheng Y, Wang S, Cai J, Ke A, Fan J. The progress of immune checkpoint therapy in primary liver cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188638. [PMID: 34688805 DOI: 10.1016/j.bbcan.2021.188638] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
222 Zhou JC, Wang JL, Ren HZ, Shi XL. Autophagy plays a double-edged sword role in liver diseases. J Physiol Biochem 2021. [PMID: 34657993 DOI: 10.1007/s13105-021-00844-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
223 Krishnamurthy S, Gilot D, Ahn SB, Lam V, Shin JS, Guillemin GJ, Heng B. Involvement of Kynurenine Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5180. [PMID: 34680327 DOI: 10.3390/cancers13205180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
224 Musto J, Spengler EK, German MN. Sexual Dimorphisms in Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2021;20:97-107. [DOI: 10.1007/s11901-021-00568-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Zhang WY, Zhan HL, Li MK, Wu GD, Liu Z, Wu LF. Long noncoding RNA Gas5 induces cell apoptosis and inhibits tumor growth via activating the CHOP-dependent endoplasmic reticulum stress pathway in human hepatoblastoma HepG2 cells. J Cell Biochem 2021. [PMID: 34636091 DOI: 10.1002/jcb.30159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
226 Dai Y, Jiang H, Jiang H, Zhao S, Zeng X, Sun R, Zheng R. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis. Transl Oncol 2021;14:101238. [PMID: 34628285 DOI: 10.1016/j.tranon.2021.101238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
227 Qin L, Huang D, Huang J, Qin F, Huang H. Integrated Analysis and Finding Reveal Anti-Liver Cancer Targets and Mechanisms of Pachyman (Poria cocos Polysaccharides). Front Pharmacol 2021;12:742349. [PMID: 34603055 DOI: 10.3389/fphar.2021.742349] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
228 Bian J, Zhang D, Wang Y, Qin H, Yang W, Cui R, Sheng J. Mitochondrial Quality Control in Hepatocellular Carcinoma. Front Oncol 2021;11:713721. [PMID: 34589426 DOI: 10.3389/fonc.2021.713721] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
229 Sufyan M, Ali Ashfaq U, Ahmad S, Noor F, Hamzah Saleem M, Farhan Aslam M, El-Serehy HA, Aslam S. Identifying key genes and screening therapeutic agents associated with diabetes mellitus and HCV-related hepatocellular carcinoma by bioinformatics analysis. Saudi J Biol Sci 2021;28:5518-25. [PMID: 34588861 DOI: 10.1016/j.sjbs.2021.07.068] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
230 Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, Seo YS, Lee HA, Park SY, Lim YS, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim JJ, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Jang MJ, Lee YB, Kim YJ, Yoon JH, Papatheodoridis GV, Lee JH. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. J Hepatol 2021:S0168-8278(21)02087-0. [PMID: 34606915 DOI: 10.1016/j.jhep.2021.09.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
231 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
232 Mattos ÂZ, Debes JD, Dhanasekaran R, Benhammou JN, Arrese M, Patrício ALV, Zilio AC, Mattos AA. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World J Hepatol 2021; 13(9): 1107-1121 [PMID: 34630878 DOI: 10.4254/wjh.v13.i9.1107] [Reference Citation Analysis]
233 Lee J, Lim YS, Lee JH, Gwak GY, Do M, Yeo I, Shin D, Han D, Park T, Kim Y. Inclusive Quantification Assay of Serum Des-γ-Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry. Hepatol Commun 2021;5:1767-83. [PMID: 34558815 DOI: 10.1002/hep4.1752] [Reference Citation Analysis]
234 Inukai Y, Imai N, Yamamoto K, Ito T, Ishizu Y, Honda T, Okamoto S, Kanematsu T, Suzuki N, Matsushita T, Ishigami M, Fujishiro M. The influence of hepatitis C virus eradication on hepatocarcinogenesis in patients with hemophiliaHCC after HCV eradication in hemophilia. Ann Hepatol 2021;27:100545. [PMID: 34571264 DOI: 10.1016/j.aohep.2021.100545] [Reference Citation Analysis]
235 Lee HA, Chu KB, Moon EK, Quan FS. Glutathione Peroxidase 8 Suppression by Histone Deacetylase Inhibitors Enhances Endoplasmic Reticulum Stress and Cell Death by Oxidative Stress in Hepatocellular Carcinoma Cells. Antioxidants (Basel) 2021;10:1503. [PMID: 34679638 DOI: 10.3390/antiox10101503] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
236 Gao C, Shen J, Chen W, Yao L, Liang X, Zhu R, Chen Z. Increased RBM12 expression predicts poor prognosis in hepatocellular carcinoma based on bioinformatics. J Gastrointest Oncol 2021;12:1905-26. [PMID: 34532138 DOI: 10.21037/jgo-21-390] [Reference Citation Analysis]
237 Guo T, He K, Wang Y, Sun J, Chen Y, Yang Z. Prognostic Signature of Hepatocellular Carcinoma and Analysis of Immune Infiltration Based on m6A-Related lncRNAs. Front Oncol 2021;11:691372. [PMID: 34527575 DOI: 10.3389/fonc.2021.691372] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
238 Qayum K, Kar I, Rashid U, Nawaz G, Krishnakumar P, Sudarshan V, Syed A. Effects of surgery, chemotherapy, and radiation on hepatocellular carcinoma patients: A SEER-based study. Ann Med Surg (Lond) 2021;69:102782. [PMID: 34522376 DOI: 10.1016/j.amsu.2021.102782] [Reference Citation Analysis]
239 Mattos ÂZ, Debes JD, Boonstra A, Vogel A, Mattos AA. Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. World J Gastrointest Oncol 2021; 13(9): 1132-1143 [PMID: 34616518 DOI: 10.4251/wjgo.v13.i9.1132] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
240 Xu W, Lu X, Liu J, Chen Q, Huang X, Huang K, Liu H, Zhu W, Zhang X. Identification of PAFAH1B3 as Candidate Prognosis Marker and Potential Therapeutic Target for Hepatocellular Carcinoma. Front Oncol 2021;11:700700. [PMID: 34490100 DOI: 10.3389/fonc.2021.700700] [Reference Citation Analysis]
241 Chen X, Zhang H, Ou S, Chen H. Von Hippel-Lindau gene single nucleotide polymorphism (rs1642742) may be related to the occurrence and metastasis of HBV-related hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27187. [PMID: 34477178 DOI: 10.1097/MD.0000000000027187] [Reference Citation Analysis]
242 Kawaguchi K, Sakai Y, Terashima T, Shimode T, Seki A, Orita N, Takeshita Y, Shimakami T, Takatori H, Arai K, Kitamura K, Yamashita T, Yamashita T, Takamura M, Mizukoshi E, Takamura T, Honda M, Wada T, Kaneko S. Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease. Medicine (Baltimore) 2021;100:e26835. [PMID: 34397849 DOI: 10.1097/MD.0000000000026835] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
243 Jin X, Yin J, Zhu H, Li W, Yu K, Liu M, Zhang X, Lu M, Wan Z, Huang X. SMG9 Serves as an Oncogene to Promote the Tumor Progression via EMT and Wnt/β-Catenin Signaling Pathway in Hepatocellular Carcinoma. Front Pharmacol 2021;12:701454. [PMID: 34456727 DOI: 10.3389/fphar.2021.701454] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
244 Dolicka D, Foti M, Sobolewski C. The Emerging Role of Stress Granules in Hepatocellular Carcinoma. Int J Mol Sci 2021;22:9428. [PMID: 34502337 DOI: 10.3390/ijms22179428] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
245 Ren AH, Xu H, Yang DW, Zhang N, Ba T, Wang ZC, Yang ZH. Systematic Training of Liver Imaging Reporting and Data System Magnetic Resonance Imaging v2018 can Improve the Diagnosis of Hepatocellular Carcinoma for Different Radiologists. J Clin Transl Hepatol 2021;9:537-44. [PMID: 34447683 DOI: 10.14218/JCTH.2021.00180] [Reference Citation Analysis]
246 Mancuso A, Pourfathi M, Kiefer RM, Noji MC, Siddiqui S, Profka E, Weber CN, Pantel A, Kadlecek SJ, Rizi R, Gade TPF. Radial Flow Perfusion Enables Real-Time Profiling of Cellular Metabolism at Low Oxygen Levels with Hyperpolarized 13C NMR Spectroscopy. Metabolites 2021;11:576. [PMID: 34564392 DOI: 10.3390/metabo11090576] [Reference Citation Analysis]
247 Loneker AE, Wells RG. Perspective: The Mechanobiology of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4275. [PMID: 34503085 DOI: 10.3390/cancers13174275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Huang LH, Hsieh TM, Huang CY, Liu YW, Wu SC, Chien PC, Hsieh CH. Disparity of Hepatocellular Carcinoma in Tumor Microenvironment-Related Genes and Infiltrating Immune Cells between Asian and Non-Asian Populations. Genes (Basel) 2021;12:1274. [PMID: 34440448 DOI: 10.3390/genes12081274] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
249 Verma M, Paik JM, Younossi I, Tan D, Abdelaal H, Younossi ZM. The impact of hepatocellular carcinoma diagnosis on patients' health-related quality of life. Cancer Med 2021;10:6273-81. [PMID: 34405568 DOI: 10.1002/cam4.4166] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
250 Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R, Foltran L, Ongaro E, Puglisi F. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. Cells 2021;10:2034. [PMID: 34440803 DOI: 10.3390/cells10082034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
251 Lambrecht J, Porsch-Özçürümez M, Best J, Jost-Brinkmann F, Roderburg C, Demir M, Tacke F, Mohr R. The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis. J Clin Med 2021;10:3392. [PMID: 34362181 DOI: 10.3390/jcm10153392] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
252 Pezzuto F, Izzo F, De Luca P, Biffali E, Buonaguro L, Tatangelo F, Buonaguro FM, Tornesello ML. Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3771. [PMID: 34359670 DOI: 10.3390/cancers13153771] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
253 Khan R, Ghazali FM, Mahyudin NA, Samsudin NIP. Aflatoxin Biosynthesis, Genetic Regulation, Toxicity, and Control Strategies: A Review. J Fungi (Basel) 2021;7:606. [PMID: 34436145 DOI: 10.3390/jof7080606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
254 Terzi E, Ayuso C, Piscaglia F, Bruix J. Liver Imaging Reporting and Data System: Review of Pros and Cons. Semin Liver Dis 2021. [PMID: 34298576 DOI: 10.1055/s-0041-1732356] [Reference Citation Analysis]
255 Pagani I, Poli G, Vicenzi E. TRIM22. A Multitasking Antiviral Factor. Cells 2021;10:1864. [PMID: 34440633 DOI: 10.3390/cells10081864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
256 Xue C, Zhao Y, Li G, Li L. Multi-Omic Analyses of the m5C Regulator ALYREF Reveal Its Essential Roles in Hepatocellular Carcinoma. Front Oncol 2021;11:633415. [PMID: 34367948 DOI: 10.3389/fonc.2021.633415] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
257 Li Y, Luo G. Human low-density lipoprotein receptor plays an important role in hepatitis B virus infection. PLoS Pathog 2021;17:e1009722. [PMID: 34293069 DOI: 10.1371/journal.ppat.1009722] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
258 Wei J, Wang B, Gao X, Sun D. Prognostic Value of a Novel Signature With Nine Hepatitis C Virus-Induced Genes in Hepatic Cancer by Mining GEO and TCGA Databases. Front Cell Dev Biol 2021;9:648279. [PMID: 34336819 DOI: 10.3389/fcell.2021.648279] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
259 Katoh M, Katoh M. Grand Challenges in Molecular Medicine for Disease Prevention and Treatment Through Cyclical Innovation. Front Mol Med 2021;1:720577. [DOI: 10.3389/fmmed.2021.720577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
261 Kwee SA, Wong LL, Sato MM, Acoba JD, Rho YS, Srivastava A, Landsittel DP. Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Score-Matched Analysis with Target Trial Emulation. J Vasc Interv Radiol 2021;32:1258-1266.e6. [PMID: 34242775 DOI: 10.1016/j.jvir.2021.07.001] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
262 Vogt A, Sadeghlar F, Ayub TH, Schneider C, Möhring C, Zhou T, Mahn R, Bartels A, Praktiknjo M, Kornek MT, Toma M, Schmidt-Wolf IGH, Branchi V, Matthaei H, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Alpha-Fetoprotein- and CD40Ligand-Expressing Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3375. [PMID: 34282787 DOI: 10.3390/cancers13133375] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
263 Qin S, Xu J, Yi Y, Jiang S, Jin P, Xia X, Ma F. Transcription Factors and Methylation Drive Prognostic miRNA Dysregulation in Hepatocellular Carcinoma. Front Oncol 2021;11:691115. [PMID: 34307154 DOI: 10.3389/fonc.2021.691115] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
264 Swed B, Ryan K, Gandarilla O, Shah MA, Brar G. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition. Medicine (Baltimore) 2021;100:e26471. [PMID: 34160456 DOI: 10.1097/MD.0000000000026471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 de Mattos ÂZ, Debes JD, Boonstra A, Yang JD, Balderramo DC, Sartori GDP, de Mattos AA. Current impact of viral hepatitis on liver cancer development: The challenge remains. World J Gastroenterol 2021; 27(24): 3556-3567 [PMID: 34239269 DOI: 10.3748/wjg.v27.i24.3556] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
266 Zhang Z, Liu C, Akakuru O, Xu W, Wu A, Zhang Y. ICG and Sunitinib-loaded NH2-MOFs for Folate-mediated Hepatocellular Carcinoma Dual-modal Therapy. Chem Res Chin Univ 2021;37:967-74. [DOI: 10.1007/s40242-021-1206-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
267 Li B, Lam KO, Lee VH, Fang W. Editorial: Immunotherapy in Hepatocellular Carcinoma. Front Oncol 2021;11:698515. [PMID: 34178698 DOI: 10.3389/fonc.2021.698515] [Reference Citation Analysis]
268 Ogasawara S, Choo SP, Li JT, Yoo C, Wang B, Lee D, Chow PKH. Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion. Cancers (Basel) 2021;13:2626. [PMID: 34071818 DOI: 10.3390/cancers13112626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
269 Barcena-Varela M, Lujambio A. The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers (Basel) 2021;13:2621. [PMID: 34073538 DOI: 10.3390/cancers13112621] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
270 Li Z, Wang C, Li J, Liu Z, Jiao D, Han X. MR-guided microwave ablation of hepatocellular carcinoma (HCC): is general anesthesia more effective than local anesthesia? BMC Cancer 2021;21:562. [PMID: 34001036 DOI: 10.1186/s12885-021-08298-2] [Reference Citation Analysis]
271 Zhu R, Tu Y, Chang J, Xu H, Li JC, Liu W, Do AD, Zhang Y, Wang J, Li B. The Orphan Nuclear Receptor Gene NR0B2 Is a Favorite Prognosis Factor Modulated by Multiple Cellular Signal Pathways in Human Liver Cancers. Front Oncol 2021;11:691199. [PMID: 34055653 DOI: 10.3389/fonc.2021.691199] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
272 Han T, Zhou Y, Li D. Relationship between hepatocellular carcinoma and depression via online database analysis. Bioengineered 2021;12:1689-97. [PMID: 33960267 DOI: 10.1080/21655979.2021.1921552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
273 Cunha Júnior AD, Bragagnoli AC, Costa FO, Carvalheira JBC. Repurposing metformin for the treatment of gastrointestinal cancer. World J Gastroenterol 2021;27:1883-904. [PMID: 34007128 DOI: 10.3748/wjg.v27.i17.1883] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
274 Xu D, Tian Y, Xia Q, Ke B. The cGAS-STING Pathway: Novel Perspectives in Liver Diseases. Front Immunol 2021;12:682736. [PMID: 33995425 DOI: 10.3389/fimmu.2021.682736] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
275 Ricciotti E, Wangensteen KJ, FitzGerald GA. Aspirin in Hepatocellular Carcinoma. Cancer Res 2021;81:3751-61. [PMID: 33893087 DOI: 10.1158/0008-5472.CAN-21-0758] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
276 Li W, Wu H, Xu X, Zhang Y. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations. Aging (Albany NY) 2021;13:11564-94. [PMID: 33867349 DOI: 10.18632/aging.202853] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
277 Ma T, Ma Y, Du Y, Wei Z, Wang J, Jun Y, Xiao F. Circular RNA hsa_circ_0013958 Functions as an Oncogenic Gene Through Modulating miR-532-3p/WEE1 Axis in Hepatocellular Carcinoma. Front Oncol 2021;11:585172. [PMID: 33937016 DOI: 10.3389/fonc.2021.585172] [Reference Citation Analysis]
278 Sun Y, Zhou A, Zhang W, Jiang Z, Chen B, Zhao J, Li Z, Wang L, Bi X, Zhao H, Liu K. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). Hepatol Int 2021;15:621-9. [PMID: 33826043 DOI: 10.1007/s12072-021-10171-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
279 Xin Y, Yang Y, Liu N, Chen Y, Wang Y, Zhang X, Li X, Zhou X. Prognostic significance of systemic immune-inflammation index-based nomogram for early stage hepatocellular carcinoma after radiofrequency ablation. J Gastrointest Oncol 2021;12:735-50. [PMID: 34012662 DOI: 10.21037/jgo-20-342] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
280 Ciurea AM, Vere CC, Popp CG, Streba CT, Caliţa M, Pirici D, Cercelaru L, Schenker M, Gheonea DI, Pirici I. E-cadherin and aquaporin 1 co-expression analysis in hepatocellular carcinoma: a pilot study. Rom J Morphol Embryol 2021;62:427-34. [PMID: 35024730 DOI: 10.47162/RJME.62.2.08] [Reference Citation Analysis]
281 Mohr R, Jost-Brinkmann F, Özdirik B, Lambrecht J, Hammerich L, Loosen SH, Luedde T, Demir M, Tacke F, Roderburg C. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Front Immunol 2021;12:652172. [PMID: 33859646 DOI: 10.3389/fimmu.2021.652172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
282 Weng J, Zhou C, Zhou Q, Chen W, Yin Y, Atyah M, Dong Q, Shi Y, Ren N. Development and Validation of a Metabolic Gene-Based Prognostic Signature for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:193-209. [PMID: 33824863 DOI: 10.2147/JHC.S300633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
283 Ocker M, Mayr C, Kiesslich T, Stintzing S, Neureiter D. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers (Basel) 2021;13:1558. [PMID: 33805268 DOI: 10.3390/cancers13071558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
284 Pais R, Maurel T. Natural History of NAFLD. J Clin Med 2021;10:1161. [PMID: 33802047 DOI: 10.3390/jcm10061161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
285 Zhao J, Li H, Zhao S, Wang E, Zhu J, Feng D, Zhu Y, Dou W, Fan Q, Hu J, Jia L, Liu L. Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling. Mol Cancer 2021;20:46. [PMID: 33658044 DOI: 10.1186/s12943-021-01343-5] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
286 Gaia S, Ciruolo M, Ribaldone DG, Rolle E, Migliore E, Mosso E, Vola S, Risso A, Fagoonee S, Saracco GM, Carucci P. Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma. Curr Oncol 2021;28:1034-44. [PMID: 33669107 DOI: 10.3390/curroncol28020101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
287 Mohr R, Özdirik B, Lambrecht J, Demir M, Eschrich J, Geisler L, Hellberg T, Loosen SH, Luedde T, Tacke F, Hammerich L, Roderburg C. From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. Int J Mol Sci 2021;22:1492. [PMID: 33540837 DOI: 10.3390/ijms22031492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
288 Casper M, Linxweiler M, Linxweiler J, Zimmermann R, Glanemann M, Lammert F, Weber SN. SEC62 and SEC63 Expression in Hepatocellular Carcinoma and Tumor-Surrounding Liver Tissue. Visc Med 2021;37:110-5. [PMID: 33977099 DOI: 10.1159/000513293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
289 Li X, Wu S, Yu Y. Aspirin Use and the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B Virus or Hepatitis C Virus Infection: A Meta-Analysis of Cohort Studies. Front Med (Lausanne) 2020;7:569759. [PMID: 33490093 DOI: 10.3389/fmed.2020.569759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
290 Yao XQ, Li L, Piao LZ, Zhang GJ, Huang XZ, Wang Y, Liang ZL. Overexpression of Ubiquitin-Specific Protease15 (USP15) Promotes Tumor Growth and Inhibits Apoptosis and Correlated With Poor Disease-Free Survival in Hepatocellular Carcinoma. Technol Cancer Res Treat. 2020;19:1533033820967455. [PMID: 33267707 DOI: 10.1177/1533033820967455] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
291 Rakké YS, Sprengers D, Kwekkeboom J, IJzermans JNM. Camrelizumab-targeting a novel PD-1 epitope to treat hepatocellular carcinoma. Ann Transl Med 2020;8:1614. [PMID: 33437813 DOI: 10.21037/atm-2020-115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
292 Sun S, Gao J, Zhou S, Li Y, Wang Y, Jin L, Li J, Liu B, Zhang B, Han S, Ding H, Li X. A novel circular RNA circ-LRIG3 facilitates the malignant progression of hepatocellular carcinoma by modulating the EZH2/STAT3 signaling. J Exp Clin Cancer Res 2020;39:252. [PMID: 33222697 DOI: 10.1186/s13046-020-01779-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
293 Zhuang H, Zhou Z, Ma Z, Huang S, Gong Y, Zhang Z, Hou B, Yu W, Zhang C. Prognostic Stratification Based on a Novel Nomogram for Solitary Large Hepatocellular Carcinoma After Curative Resection. Front Oncol 2020;10:556489. [PMID: 33312945 DOI: 10.3389/fonc.2020.556489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
294 Frager SZ, Schwartz JM. Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve. Curr Oncol 2020;27:S138-43. [PMID: 33343207 DOI: 10.3747/co.27.7181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
295 Deng Z, Xu XY, Yunita F, Zhou Q, Wu YR, Hu YX, Wang ZQ, Tian XF. Synergistic anti-liver cancer effects of curcumin and total ginsenosides. World J Gastrointest Oncol 2020; 12(10): 1091-1103 [PMID: 33133379 DOI: 10.4251/wjgo.v12.i10.1091] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
296 Hu YT, Shu ZY, Jiang JH, Xie QF, Zheng SS. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int 2020;19:547-54. [PMID: 33051131 DOI: 10.1016/j.hbpd.2020.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
297 Zhang Y, Li Y, Wang Q, Su B, Xu H, Sun Y, Sun P, Li R, Peng X, Cai J. Role of RASA1 in cancer: A review and update (Review). Oncol Rep 2020;44:2386-96. [PMID: 33125148 DOI: 10.3892/or.2020.7807] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
298 Hong W, Liang L, Gu Y, Qi Z, Qiu H, Yang X, Zeng W, Ma L, Xie J. Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma. Mol Ther Nucleic Acids 2020;22:937-47. [PMID: 33251044 DOI: 10.1016/j.omtn.2020.10.002] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 52.5] [Reference Citation Analysis]
299 Chen K, Zhang Z, Yu A, Li J, Liu J, Zhang X. lncRNA DLGAP1-AS2 Knockdown Inhibits Hepatocellular Carcinoma Cell Migration and Invasion by Regulating miR-154-5p Methylation. Biomed Res Int 2020;2020:6575724. [PMID: 33195697 DOI: 10.1155/2020/6575724] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
300 Martínez-Chantar ML, Avila MA, Lu SC. Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment. Cancers (Basel) 2020;12:E2729. [PMID: 32977536 DOI: 10.3390/cancers12102729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
301 Fernández-Barrena MG, Arechederra M, Colyn L, Berasain C, Avila MA. Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. JHEP Rep 2020;2:100167. [PMID: 33134907 DOI: 10.1016/j.jhepr.2020.100167] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
302 Mungamuri SK, Mavuduru VA. Role of epigenetic alterations in aflatoxin‐induced hepatocellular carcinoma. Liver Cancer International 2020;1:41-50. [DOI: 10.1002/lci2.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
303 Mi N, Cao J, Zhang J, Fu W, Huang C, Gao L, Yue P, Bai B, Lin Y, Meng W, Li X. Identification of hub genes involved in the occurrence and development of hepatocellular carcinoma via bioinformatics analysis. Oncol Lett 2020;20:1695-708. [PMID: 32724412 DOI: 10.3892/ol.2020.11752] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]